ReviewJournal of orthopaedic translation2020
Sarcopenia: Current treatments and new regenerative therapeutic approaches.
Review in Journal of orthopaedic translation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 83 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dietary Modification Intervention Involving Family Support (FamNUTRI) for Managing Sarcopenic Obesity Among Community-dwelling Older Adults: a Pilot Randomized Controlled Trial
The effect of proprioceptive exercise training on cervical proprioception, kinesiophobia, and pain catastrophizing levels in sarcopenic geriatric individuals residing in nursing homes
Effect of Consumption of Vegetable Protein-enriched Biscuits and Vitamin D Supplementation on the Progression of Sarcopenia in Elderly Subjects
Who cites it
83 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of ACSM protocol-compliant exercise on sarcopenia: a systematic review and meta-analysis of randomized controlled trials.BMC geriatrics · 2026Pooled it
- Pooled it
- Pooled it
- Trial
- Interplay between sarcopenia and type 2 diabetes: mechanisms, implications, and therapeutic prospects.Nutrition & diabetes · 2026Review
- Advances in electrical stimulation-based therapeutic technologies for sarcopenia prevention and treatment.Bioactive materials · 2026Review
- Gender Differences in Circulating TFAM Levels Are Associated with Functional Impairment and Sarcopenia.Biomedicines · 2026Article
- Development of pharmacological interventions for the treatment of sarcopenia.Annals of translational medicine · 2026Review
- Review
- Sarcopenia and fall-related outcomes in Chinese adults aged 45 years or older: a longitudinal cohort study.Scientific reports · 2026Article
- An integrated drug repositioning analysis identifies rosiglitazone as a treatment for sarcopenia.Communications biology · 2026Article
- Regenerative and Wellness Medicine: A Boon or Barrier to Surgical Innovation in Degenerative Spine Care?International journal of spine surgery · 2025Article
- Amino acid metabolites as potential circulating biomarkers for sarcopenia.Scientific reports · 2025Article
- Association between a plant-based diet and the risk of sarcopenia among older adults: a case-control study.BMC public health · 2025Article
- The Diagnostic Accuracy of Biological Markers of Sarcopenia, Sarcopenic Obesity, and Osteosarcopenia: Protocol for a Systematic Review and Meta-Analysis.Health science reports · 2025Article
- Combined Protein, Probiotics, and Exercise Therapy for Sarcopenia: A Comprehensive Review.Cells · 2025Review
- ETASPharmaceuticals (Basel, Switzerland) · 2025Article
- Baicalin Improves Skeletal Muscle Atrophy by Attenuating DRP-1-Mediated Mitochondrial Fission in Aged Mice.Muscles (Basel, Switzerland) · 2025Article
- HDAC11 deficiency regulates age-related muscle decline and sarcopenia.GeroScience · 2025Article
- Macrophage Subpopulation Promotes Skeletal Muscle Regeneration Through HGF/MET Signaling-Mediated Skeletal Muscle Stem Cell Proliferation.Aging cell · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is characterized by loss of muscle and reduction in muscle strength that contributes to higher mortality rate and increased incidence of fall and hospitalization in the elderly. Mitochondria dysfunction and age-associated inflammation in muscle are two of the main attributors to sarcopenia progression. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Unlike nutraceutical and pharmaceutical interventions that showed controversial results in sarcopenia alleviation, exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signalling between muscle and bone. However, as exercise have limited benefit to immobile patients, the use of stem cells and their secretome are being suggested to be novel therapeutics that can be catered to a larger patient population owing to their mitochondria restoration effects and immune modulatory abilities. As such, we reviewed the potential pros and cons associated with various stem cell types/secretome in sarcopenia treatment and the regulatory and production barriers that need to be overcome to translate such novel therapeutic agents into bedside application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.